Hormonal Mechanisms in Atherosclerosis

1. Bittner V. Menopause, age, and cardiovascular risk: a complex relationship. J Am Coll Cardiol. 2009; 54(25):2374–5.10.1016/j.jacc.2009.10.00820082926Search in Google Scholar

2. Magnani JW, Moser CB, Murabito JM, et al. Age of natural menopause and atrial fibrillation: the Framingham Heart Study. Am Heart J. 2012; 163(4):729–34. 3 Vaidya D, Becker DM,10.1016/j.ahj.2012.01.010333486122520541Search in Google Scholar

3. Bittner V, Mathias RA, Ouyang P. Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data. BMJ. 2011; 343:d5170.10.1136/bmj.d5170316716421896608Search in Google Scholar

4. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003; 178(3):373–80.10.1677/joe.0.178037312967330Search in Google Scholar

5. Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrin Metab. 2005; 90(5):2708-2711.10.1210/jc.2004-201115687329Search in Google Scholar

6. Burke A.P., Farb A., Malcom G., Virmani R.. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis, Am Heart J, 2001; vol. 141 2:58-62.10.1067/mhj.2001.10994611174360Search in Google Scholar

7. Rossouw JE, Prentice PL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297(13):1465-1477.10.1001/jama.297.13.146517405972Search in Google Scholar

8. Peter I, Kelley-Hedgepeth A, Huggins GS, et al. Association between arterial stiffness and variations in oestrogen-related genes. J Hum Hypertens. 2009; 23(10):636-644.10.1038/jhh.2009.1274626019194457Search in Google Scholar

9. Debing E, Peeters E, Duquet W, Poppe K, Velkeniers B, Van den Brande P. Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarter-ectomy. Eur J Endocrinol. 2007; 156(6):687-69310.1530/EJE-06-070217535869Search in Google Scholar

10. Austin C.E.. Chronic and acute effects of oestrogens on vascular contractility, J Hypertens, 2000, vol. 18:1365-1378.10.1097/00004872-200018100-0000311057423Search in Google Scholar

11. HigashiY., Sanada M., Sasaki S., et al. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women, Hypertension, 2001; vol. 37:651-657.10.1161/01.HYP.37.2.651Search in Google Scholar

12. Bechlioulis A, Naka KK, Calis KA, et al. Cardiovascular Effects of Endogenous Estrogen and Hormone Therapy. Curr Vasc Pharmacol. 2010; 8:249-258.10.2174/15701611079088697419485910Search in Google Scholar

13. Badimon, L. New challenges in the etiopathogenesis of atherothrombosis. Cerebrovasc Dis 11 Suppl 1. 2001;80-84.10.1159/00004912911244204Search in Google Scholar

14 Hodges Y.K., Tung L., Yan X.D., Graham J.D., Horwitz K.B., Horwitz L.D..Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation, 2000; vol.101:1792-1798.10.1161/01.CIR.101.15.179210769279Search in Google Scholar

15. Shearman AM, Cooper JA, Kotwinski PJ, et al. Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts. Circ Res. 2006; 98(5):590-592.10.1161/01.RES.0000210578.62102.a616484614Search in Google Scholar

16. Hodges YK, Tung L, Yan XD, Graham JD, Horwitz KB, Horwitz LD. Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation. 2000; 101(15):1792-1798.10.1161/01.CIR.101.15.1792Search in Google Scholar

17. Schuit SC, Oei HH, Witteman JC, et al. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA. 2004; 291(24):2969-2977.10.1001/jama.291.24.296915213208Search in Google Scholar

18. Schuit SC, de Jong FH, Stolk L, et al. Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women. Eur J Endocrinol. 2005; 153(2):327-334.10.1530/eje.1.0197316061840Search in Google Scholar

19. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003; 178(3):373–80.10.1677/joe.0.178037312967330Search in Google Scholar

20. Liu PY, Death AK, Handelsman DJ. Androgens and cardio-vascular disease. Endocr Rev. 2003; 24(3):313-340.10.1210/er.2003-000512788802Search in Google Scholar

21. Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009; 94(7):2353-2359.10.1210/jc.2008-2416Search in Google Scholar

22. Gonzalez-Clemente JM, Gimenez-Palop O, Vilardell C, Caixas A, Gimenez-Perez G. Are statins analogues of vitamin D? Lancet. 2006; 368(9543):1233.10.1016/S0140-6736(06)69507-XSearch in Google Scholar

23. Perez-Castrillon JL, Vega G, Abad L, et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007; 99(7):903-905.10.1016/j.amjcard.2006.11.03617398180Search in Google Scholar

24. Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care. 2008; 11(1):7-12.10.1097/MCO.0b013e3282f2f4dd18090651Search in Google Scholar

25. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men:a prospective study. Arch Intern Med. 2008; 168(11):1174-1180.10.1001/archinte.168.11.1174371939118541825Search in Google Scholar

26. Pilz S, Dobnig H, Nijpels G, et al. Vitamin D and mortality in older men and women. Clin Endocrinol (Oxf). 2009; 71(5):666-672.10.1111/j.1365-2265.2009.03548.x19226272Search in Google Scholar

27. Wannamethee SG, Tchernova J, Whincup P, et al. Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis. 2007; 191(2):418-426.10.1016/j.atherosclerosis.2006.04.01216712853Search in Google Scholar

28. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004; 44(9):1819-1824.10.1016/j.jacc.2004.07.05015519013Search in Google Scholar

29. Kizer J, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrin Metab. 2008; 93(9):3357-3364.10.1210/jc.2008-0640256785318593765Search in Google Scholar

30. Butler J, Kalogeropoulos A, Georgiopoulou V, et al, for the Health ABC Study. Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study. Arterioscler Thromb Vasc Biol. 2009; 29(7):1144-1149.10.1161/ATVBAHA.109.186783275729019372460Search in Google Scholar

31. Frankel DS, Vasan RS, D’Agostino RB Sr, et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol. 2009; 53(9):754-762.10.1016/j.jacc.2008.07.073267679319245965Search in Google Scholar

32. Bonaa K, Njolstad I, Ueland P. NORVIT trial investigators. Homocysteine lowering and cadiovascular evens after acute myocardial infarction. N Engl J Med. 2006; 354(15):1578-1588.10.1056/NEJMoa05522716531614Search in Google Scholar

33. Shi RZ, Wang JC, Huang SH, Wang XJ, Li QP. Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp Cell Res. 2009; 315(1):10-15.10.1016/j.yexcr.2008.09.02418973754Search in Google Scholar

34. Shan H, Bai X, Chen X. Angiotensin II induces endothelial cell senescence via the activation of mitogen-activated protein-kinases. Cell Biochem Funct. 2008; 26(4):459-466.10.1002/cbf.146718383564Search in Google Scholar

35. Javeshghani D, Sairam MR, Neves MF, Schiffrin EL, Touyz RM. Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension. J Hypertens. 2006; 24(7):1365-1373.10.1097/01.hjh.0000234117.25401.f816794486Search in Google Scholar

36. Vinh A, Widdop RE, Drummond GR, Gaspari TA. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res. 2008; 77(1):178-187.10.1093/cvr/cvm02118006471Search in Google Scholar

37. Sluimer JC, Gasc JM, Hamming I, et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J Pathol. 2008; 215(3):273-279.10.1002/path.235718498093Search in Google Scholar

38. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Archives o f Internal Medicine. 2003; 163(10):1155–1164.10.1001/archinte.163.10.115512767951Search in Google Scholar

39. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. Journal of Internal Medicine. 2008; 264(3):224–236.10.1111/j.1365-2796.2008.01981.x716693018793332Search in Google Scholar

40. Toko H, Zou Y, Minamino T, Masaya M, Harada M, Nagai T, Sugaya T, Terasaki F, Kitaura Y, Komuro I. Angiotensin II type 1a receptor is involved in cell infiltration, cytokine production, and neovascularization in infarcted myocardium. Arterioscler Thromb Vasc Biol. 2004; 24:664–670.10.1161/01.ATV.0000122361.63827.ab14962948Search in Google Scholar

41. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008; 57(12):3297–3306.10.2337/db08-0805Search in Google Scholar

42. Singh VP, Baker KM, Kumar R. Activation of the intracellular reninangiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. American Journal of Physiology. 2008; 294(4):H1675–H1684.10.1152/ajpheart.91493.2007Search in Google Scholar

43. Kumar R, Singh VP, Baker KM. The intracellular reninangiotensin system: implications in cardiovascular remodeling. Current Opinion in Nephrology and Hypertension. 2008; 17(2):168–173.10.1097/MNH.0b013e3282f521a8Search in Google Scholar

44. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Reninangiotensin system and cardiovascular risk. The Lancet. 2007; 369(9568):1208–1219.10.1016/S0140-6736(07)60242-6Search in Google Scholar

45. Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev. 2008; 29(2):133-154.10.1210/er.2007-003018292466Search in Google Scholar

46. Francis GS, Tang WH. Should we consider aldosterone as the primary screening target for preventing cardiovascular events? J Am Coll Cardiol. 2005; 45:1249-1250.Search in Google Scholar

47. Stowasser M. New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol. 2001; 28:783-791.10.1046/j.1440-1681.2001.03523.x11553016Search in Google Scholar

48. Marney, A. M., and Brown, N. J. Aldosterone and end-organ damage. Clin. Sci. (Lond.) 2007; 113:267–278.Search in Google Scholar

49. Turgeon J, McDonnell D, Martin K, Wise P. Hormone therapy: physiological complexity belies therapeutic simplicity. Science. 2004; 304(5676):1269-1273.10.1126/science.109672515166356Search in Google Scholar

50. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007; 356(25):2591-2602.10.1056/NEJMoa07151317582069Search in Google Scholar

51. Rossouw JE, Prentice PL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297(13):1465-1477.10.1001/jama.297.13.146517405972Search in Google Scholar

52.Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis, N Engl J Med. 2000; vol. 343:522 -529.10.1056/NEJM20000824343080110954759Search in Google Scholar

53. Manson JE, Allison MA, Rossouw JE, et al, Estrogen therapy and coronary-artery calcification. N Eng J Med. 2007; 365:2591-2602.Search in Google Scholar

54. Tanis BC, V M, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, Van Der Graaf Y, Rosendaal FR. Oral Contraceptives and the Risk of Myocardial Infarction. N Engl J Med. 2001; 345:1787–93.10.1056/NEJMoa003216Search in Google Scholar

55. Lidegaard O. Smoking and use of oral contraceptives: impact on thrombotic diseases. Am J Obstet Gynecol. 1999; 180:S357–63.10.1016/S0002-9378(99)70696-4Search in Google Scholar

56. Mitchell, J.H. et al. Antioxidant efficacy of phytoestrogens in chemical and biological model systems. Arch Biochem Biophys. 1998; 360:142-148.10.1006/abbi.1998.09519826439Search in Google Scholar

57. Kirk, E.A. et al. Dietary isoflavones reduce plasma cholesterol and atherosclerosis in C57BL/6 mice but not LDL receptor-deficient mice. J Nutr. 1998; 128, 954-959.Search in Google Scholar

58. Anthony, M.S., Clarkson, T.B. and Williams, J.K. Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am J Clin Nutr. 1998; 68, 1390S-1393S.10.1093/ajcn/68.6.1390S9848505Search in Google Scholar